The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global glycomics market reached a value of US$ 1.21 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.52 Billion by 2027, exhibiting a CAGR of 12.80% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Glycomics refers to a study that aids in defining or quantifying the glycome of a cell, tissue, or organism. It mainly assists in identifying the structure and function of the complete set of glycans produced in a single organism and determining all the genes that encode glycoproteins. It also aids in establishing the role of carbohydrate-protein interactions in cell-cell communication. As a result, glycomics finds extensive application in diagnostics, drug discovery, and immunology across the globe.
Presently, there is a rise in the prevalence of chronic diseases on account of sedentary lifestyles and the growing number of individuals who smoke and consume alcohol. In line with this, the coronavirus disease (COVID-19) outbreak has positively influenced the demand for vaccine and treatment drugs to prevent the spread of the pandemic worldwide. This, in turn, is strengthening the growth of the glycomics market. Besides this, glycomics is gaining preference for training and educational purposes around the world. This, in confluence with its extensive applicability in research centers due to the increasing adoption of glycan structure data analysis, is contributing to market growth. Furthermore, leading market players are continuously funding research and development (R&D) activities to enhance the ability of structurally complex glycans to be employed as therapeutics. Consequently, they are developing advanced technologies, such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and capillary electrophoresis (CE) in chemical and biochemical research. Moreover, a growing number of Contract Research Organizations (CROs) for the development and production of drugs and biologics is driving the market. Some of the other factors, such as the thriving pharmaceutical industry, rising number of clinical trials, and the improving healthcare infrastructure, are anticipated to propel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global glycomics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Asparia Glycomics, Bruker Corporation, Danaher Corporation, Dextra Laboratories Limited (New Zealand Pharmaceuticals Limited), Merck KGaA, New England Biolabs, RayBiotech Life Inc., Shimadzu Corporation, Takara Bio Inc., Thermo Fisher Scientific Inc. and Waters Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Asparia Glycomics, Bruker Corporation, Danaher Corporation, Dextra Laboratories Limited (New Zealand Pharmaceuticals Limited), Merck KGaA, New England Biolabs, RayBiotech Life Inc., Shimadzu Corporation, Takara Bio Inc., Thermo Fisher Scientific Inc. and Waters Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at